Lambert-Eaton myasthenic syndrome (LEMS) is a rare autoimmune disorder where antibodies attack the nerve endings that control your muscles, causing progressive weakness that typically starts in the upper legs and hips. It affects roughly 1 to 3 people per million, and in about half of all cases, it appears as the first sign of an underlying cancer. The other half of cases arise on their own as a standalone autoimmune condition.
How LEMS Disrupts the Nerve-Muscle Connection
For a muscle to contract, nerve endings need to release a chemical messenger called acetylcholine. That release depends on calcium flowing into the nerve terminal through tiny channels. In LEMS, the immune system produces antibodies that target these calcium channels, specifically a type called P/Q-type channels. The antibodies cause the channels to cluster together and get pulled off the nerve surface, reducing their total number. With fewer calcium channels, less calcium enters the nerve ending, less acetylcholine gets released, and the signal to the muscle arrives weak.
This is different from myasthenia gravis, a more common condition that’s often confused with LEMS. In myasthenia gravis, the problem is on the muscle side of the junction. In LEMS, the problem is on the nerve side. That distinction produces some key differences in how the two conditions behave.
The Cancer Connection
Between 40% and 62% of people diagnosed with LEMS turn out to have small cell lung cancer. In almost all of these cases, the neurological symptoms appear before the cancer is found. In one case series of 24 patients, only one had a cancer diagnosis before developing LEMS symptoms.
This happens because small cell lung cancer cells express the same calcium channels found on nerve endings. The immune system mounts an attack against the tumor, and the antibodies it produces cross-react with the channels on healthy nerves. In a sense, the immune system is doing something useful by fighting the cancer, but it causes collateral damage to the nervous system in the process. When LEMS is linked to cancer, it’s classified as paraneoplastic LEMS. When no cancer is found, it’s called autoimmune LEMS. The two forms occur at roughly equal rates.
Because of this strong cancer link, anyone diagnosed with LEMS will typically undergo thorough screening for small cell lung cancer, including chest imaging. If the initial scan is clear, repeat screening is usually recommended over the following years.
What LEMS Feels Like
The hallmark symptom is weakness in the muscles closest to the trunk of your body, particularly the thighs and hips. People often first notice difficulty getting up from a chair, climbing stairs, or walking. The weakness pattern is usually symmetrical and progresses from the legs upward toward the arms and eventually the muscles of the face and throat, though significant eye and swallowing problems are less prominent than in myasthenia gravis.
Autonomic dysfunction is strikingly common, affecting 80% to 96% of patients. Dry mouth is the most frequently reported symptom. Other autonomic issues include constipation, erectile dysfunction in men, lightheadedness when standing up, and changes in sweating.
One of the most distinctive features of LEMS is what happens with reflexes. A doctor tapping your knee or ankle will find reflexes that are profoundly reduced or completely absent. This never happens in myasthenia gravis, where reflexes remain normal, making it a useful clue during a physical exam.
The Paradox of Exercise
LEMS has an unusual quirk: brief physical exertion can temporarily improve strength rather than make it worse. After a few seconds of sustained muscle contraction, calcium builds up enough at the nerve terminal to partially overcome the blockade, and the muscle responds better. A doctor might test your grip strength, ask you to squeeze repeatedly for 10 to 15 seconds, then test again and find it’s noticeably stronger. Reflexes can also temporarily return to normal after exercise. This “post-exercise facilitation” is characteristic of LEMS and helps distinguish it from myasthenia gravis, where exercise makes weakness worse.
How LEMS Is Diagnosed
Diagnosis relies on a combination of clinical findings, nerve conduction testing, and antibody blood tests.
The key electrical test is called repetitive nerve stimulation. A nerve is stimulated repeatedly while the response from the muscle is measured. In LEMS, the initial muscle response is small because so little acetylcholine is being released at rest. After the patient exercises briefly or the nerve is stimulated at high frequency, the response jumps dramatically. An increase of 100% or more is considered specific to LEMS. While smaller increases of 25% to 42% can raise suspicion, increments up to 92% have been seen in myasthenia gravis, so the 100% threshold is what clinicians rely on to confirm the diagnosis. In one study of 59 LEMS patients, 98% showed abnormalities on low-frequency stimulation, and 88% had the characteristic large post-exercise increase in at least one muscle tested.
A blood test for antibodies against P/Q-type calcium channels supports the diagnosis, though not every LEMS patient tests positive. When the antibodies are present, they’re highly suggestive, but a negative result doesn’t rule the condition out.
Treatment and What to Expect
For people with paraneoplastic LEMS, treating the underlying cancer is the most important step. Successful cancer treatment often leads to meaningful improvement in the neurological symptoms as well, since the source of the immune trigger is being addressed.
For symptom relief in both forms of LEMS, the primary medication works by a clever workaround. Rather than trying to fix the calcium channels directly, the drug (amifampridine) blocks potassium channels on the nerve ending. This keeps the nerve terminal electrically active for longer, giving the remaining calcium channels more time to open and let calcium in. The result is more acetylcholine release and stronger muscle contractions. In open-label trials involving 128 patients, 96% experienced improvement in muscle strength or daily functioning. The medication is taken in divided doses throughout the day because of its short duration of action, with a maximum daily dose of 80 mg for adults. That ceiling was established after seizures occurred in patients taking higher amounts.
When amifampridine alone isn’t enough, immunosuppressive treatments can help by dampening the antibody production that drives the disease. Intravenous immunoglobulin (IVIG) has been shown in controlled trials to produce short-term improvements in muscle strength, though it’s generally reserved for patients who don’t respond adequately to other approaches. Longer-term immune-suppressing medications may also be added to reduce antibody levels over time.
Living With LEMS
LEMS is a chronic condition, but most people maintain meaningful function with treatment. The weakness tends to progress slowly, and the combination of symptomatic medication and immune-directed therapy keeps many patients mobile and independent. For those with the paraneoplastic form, prognosis depends heavily on how the cancer responds to treatment. For those with autoimmune LEMS, the condition is generally manageable over the long term, though it requires ongoing medication and monitoring.
Because LEMS is so rare, many patients wait months or longer before receiving a correct diagnosis. The combination of leg weakness, dry mouth, and diminished reflexes, especially in a current or former smoker, should prompt consideration of this condition. Earlier recognition means earlier cancer screening and faster access to effective treatment.